Abstract:Purpose of review: Recent translational studies in osteosarcoma are discussed with the purpose to shed light on the new molecular therapeutic targets. Recent findings: The genetic aberrations of vascular endothelial growth factor (VEGF), mammalian target of rapamycin, Wnt signaling pathway, the inactivation of p53, Rb, WWOX genes, and amplification of APEX1, c-myc, RECQL4, RPL8, MDM2, VEGFA might be involved in the pathogenesis of osteosarcoma. The promising therapeutic targets for osteosarcoma patients include: integrin, ezrin, statin, NOTCH/HES1, matrix metalloproteinases (MMPs), m-calpain, and Src, which are involved in tumor cell invasion and metastasis; aldolase A, fructose-bisphosphate, sulfotransferase family 3A, member 1, BCL2-associated athanogene 3, heat shock protein 70 (HSP70), B-cell lymphoma 2-interacting mediator (BIM), polo-like kinase 1, hypoxia inducible factor 1, alpha subunit, minibrain-related kinase, Bcl-xl, caspase-3, midkine, high mobility group box 1 protein (HMGB1), and Beclin1, which are involved in tumor proliferation and apoptosis; met proto-oncogene (hepatocyte growth factor receptor), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, insulin-like growth factor (IGF)-1R, fms-related tyrosine kinase 4, platelet-derived growth factor receptor, beta polypeptide, IGF-I/II, and c-kit, which are involved in tumor growth; endosialin, VEGF, thrombin, and MMPs, which are involved in tumor angiogenesis; transforming growth factor-α/β, parathyroid hormone-like hormone, interleukin-6, interleukin-11, receptor activator of nuclear factor-κB ligand, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1, and cathepsin, which are involved in osteoclast function; Myc, HSP90, p-Met, p-Akt, p-STAT3, and cyclin D1, which are transcriptional factors; p-GP, hydroxysteroid (17-beta) dehydrogenase 10, HMGB1, BIM, inorganic phosphate, Bcl-2, PARP, mdm2, p21, Bax, and mitogen-activated protein kinase 1, which are involved in drug sensitivity. Furthermore, microRNAs such as miR-215 are also therapeutic targets. Summary: These translational studies in osteosarcoma have identified new molecular targets for osteosarcoma.

Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities

Osteosarcoma and Metastasis

Molecular Pathogenesis and Therapeutic Strategies of Human Osteosarcoma

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Bone Microenvironment and Osteosarcoma Metastasis

Molecular Treatment Strategies and Surgical Reconstruction for Metastatic Bone Diseases

Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma

Research progress on the mechanism of metastasis and invasion of osteosarcoma

Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies

Molecular targeted therapy of osteosarcoma and related clinical

Osteoporosis As a Potential Contributor to the Bone Metastases.

Current Status and Prospects of Targeted Therapy for Osteosarcoma

Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma

Osteoclasts in Osteosarcoma: Mechanisms, Interactions, and Therapeutic Prospects

Advances in molecular pathogenesis of osteosarcoma

Tumor-Stroma Interactions in Bone Metastasis: Molecular Mechanisms and Therapeutic Implications.

Epigenetic changes in osteosarcoma

Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis

New molecular insights into osteosarcoma targeted therapy

Molecular mechanisms and clinical management of cancer bone metastasis

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment